Barnard Abbey, Konyn Peter, Saab Sammy
Dr Barnard is a resident physician in the Department of Internal Medicine at the University of California, Los Angeles in Los Angeles, California. Mr Konyn is a medical student at the David Geffen School of Medicine at the University of California, Los Angeles. Dr Saab is a professor in the Departments of Internal Medicine and Surgery at the University of California, Los Angeles.
Gastroenterol Hepatol (N Y). 2016 Oct;12(10):601-608.
Improved short- and long-term survival of liver transplant recipients has led to increased focus on complications of both the early and late posttransplant periods. A variety of metabolic complications have been observed in the post-orthotopic liver transplant population, including hypertension, hyperlipidemia, obesity, diabetes mellitus, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis. Although only a small proportion of patients experience metabolic complications prior to transplantation, the prevalence of these complications posttransplantation reaches or exceeds that of the general population. This is of particular concern, as cardiovascular disease is the second leading cause of death in the late transplant period. A number of mechanisms mediate these metabolic complications, including reversal of cirrhosis pathophysiology, patient lifestyle factors, and immunosuppressive medications. Titration and modification of immunosuppression have been demonstrated to improve and sometimes even eliminate these conditions. Therefore, given the multiple etiologies contributing to the metabolic derangements, an effective management approach must incorporate lifestyle modifications, immunosuppression titration, and medical management. Best practices and understanding of the mechanisms underlying these complications allow for discussion of initial therapies and strategies; however, further study is necessary to determine the optimal management of metabolic complications over time.
肝移植受者短期和长期生存率的提高,使得人们更加关注移植后早期和晚期的并发症。原位肝移植人群中观察到了多种代谢并发症,包括高血压、高脂血症、肥胖症、糖尿病、非酒精性脂肪性肝病和非酒精性脂肪性肝炎。虽然只有一小部分患者在移植前出现代谢并发症,但移植后这些并发症的患病率达到或超过了普通人群。这尤其令人担忧,因为心血管疾病是移植后期的第二大死亡原因。多种机制介导这些代谢并发症,包括肝硬化病理生理学的逆转、患者生活方式因素和免疫抑制药物。已证明调整和改变免疫抑制可改善甚至消除这些情况。因此,鉴于导致代谢紊乱的病因多种多样,有效的管理方法必须包括生活方式改变、免疫抑制调整和药物治疗。对这些并发症潜在机制的最佳实践和理解有助于讨论初始治疗方法和策略;然而,随着时间的推移,仍需要进一步研究以确定代谢并发症的最佳管理方法。